October 20, 2020 at 09:17PM Benefit-Risk Factors to Consider When Determining Substantial Equivalence in Premarket Notifications (510(k)) with Different Technological Characteristics

This guidance document describes factors FDA uses to evaluate the benefit-risk profile of a device in comparison to a predicate device in a 510(k).

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/31sLZRU